When businesses receive a proposal from a contract development and manufacturing organisation (CDMO), it’s much like a first date: first impressions matter. The proposal process not only reveals a CDMO’s services but also hints at the potential relationship’s quality. This is gauged mainly through metrics like timing, quality, and price.
Derisking drug programs by early lead optimisation
BackgroundAntibody engineering?The development of therapeutic antibodies is a time and cost intensive process. Biological and physicochemical properties of the lead molecules influence almost every step in the development. Investing into antibody engineering and lead optimisation during early development pays off in later steps and does not only accelerate the programme, but also increases the chance of success.
Evotech screens cancer candidates for Dewpoint Therapeutics
Latest NewsGerman Evotec SE and Boston-based Dewpoint Therapeutics Inc have entered into a strategic partnership in oncology.
Pierre Fabre SA licences immunotherapy from Atara Biotherapeutics
Latest NewsPierre Fabre Laboratories SA has extended its global partnership with Atara Biotherapeutics, licencing tabelecleucel commercialisation rights for Northern America and beyond.
Scotland boosts bio-based manufacturing with £75m fund
Latest NewsBiotech companies in Scotland’s thriving bio-based manufacturing have been invited to apply for up to £1m funding within the Launchpad programme.
Memo Therapeutics AG raises CHF25m
Latest NewsSwiss Memo Therapeutics AG will use CHF25m raised in a new Series C financing to complete a Phase II study with Anti-BKV for prevention of virus-induced graft damage.
microRNA could offer a safe target in atherosclerosis
Latest NewsResearchers led by Wolfgang Enard from LMU Munich have identified a microRNA-based mechanism that drives atherosclerosis by weakening the integrity of blood vessel walls.
Paving the way to internationalisation
Sponsored PublicationsDue to the global niche character of pharmaceutical biotechnology, research collaborations and market entries on an international level are essential. Agility and market knowledge are required to maintain an overview in a rapidly evolving environment and to initiate a sustainable internationalisation process.
Navigating the CDMO proposal process
BackgroundWhen businesses receive a proposal from a contract development and manufacturing organisation (CDMO), it’s much like a first date: first impressions matter. The proposal process not only reveals a CDMO’s services but also hints at the potential relationship’s quality. This is gauged mainly through metrics like timing, quality, and price.
Cellectis and AstraZeneca in US$2.2bn deal
Latest NewsAstraZeneca plc has paid French cancer cell therapy developer Cellectis SA US$25m upfront and US$220m in equity in an US$2.2bn R&D deal for up to ten cell and gene therapies.
Alfasigma SpA set to take over Galapagos programme
Latest NewsItalian pharma company Alfasigma SpA has signed a letter of intent to acquire the filgotinib business from Galapagos.